Table 1.
|
|
Study day |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Treatment group | 0 | 7 | 14 | 21 | 28 | 35 | 42 | 49 | 56 | 63 | |
C (control) |
Geometric Means |
42.2 a |
30.6 a |
49.0 a |
98.6 a |
94.7 a |
86.1 a |
74.7 a |
53.0 a |
39.7 a |
34.6 a |
|
Totals |
520 |
344 |
804 |
1,142 |
1,077 |
1,024 |
843 |
700 |
435 |
404 |
B (spinosad) |
Geometric Means |
47.5 a |
14.0 a |
15.4 b |
17.5 b |
2.2 b |
0.4 b |
1.8 b |
1.5 b |
0.3 b |
0.2 b |
|
Totals |
527 |
191 |
201 |
208 |
30 |
11 |
29 |
25 |
5 |
4 |
|
% Reduction vs. Controls |
- |
54.1% |
68.6% |
82.2% |
97.6% |
99.5% |
97.6% |
97.1% |
99.3% |
99.5% |
A (imidacloprid + PPF) |
Geometric Means |
47.7 a |
1.4 b |
1.3 c |
1.7 c |
0.3 c |
0.2 b |
0.4 c |
0.1 c |
0.0 b |
0.0 b |
|
Totals |
519 |
32 |
23 |
28 |
6 |
3 |
5 |
2 |
0 |
0 |
% Reduction vs. Controls |
- | 95.5% | 97.4% | 98.3% | 99.7% | 99.7% | 99.5% | 99.7% | 100% | 100% |
For each study day, means followed by different letters indicate a significant difference between the treatments (p < 0.03).